Alembic Limited · NSE:ALEMBICLTD
Alembic — Q1 FY2011 Earnings Presentation
8 slides from Alembic's earnings presentation, Jun 30, 2010
Slide 1: Investors Update – Q1FY11
Investors Update – Q1FY11 • Net sales at Rs 283 crores • Export regulatory formulation sales up by 44% to Rs. 26.97 crores vis-à-vis Rs. 18.73 crores • Domestic formulations sales up 5% for the quarter ended June 30 2010 and sales at Rs. 145 crores against Rs. 137 crores in corresponding period prev
Slide 2: Management Discussion – Q1FY11
Management Discussion – Q1FY11 Alembic Limited reported sales for the quarter ended June 30 2010 at Rs 283 crores (down by 3%) compared to Rs 292 crores in corresponding quarter previous year. Company posted a net profit of Rs. 11.48 crores for the quarter ended June 30, 2010 against profit of Rs 12
Slide 3: Increase in market share in therapeutic areas
There has been an increase in market share in the following therapeutic areas. JUN MAT JUN MAT Therapeutic areas 10 09 ANTI DIABETIC 1.23 1.06 ORTHO 1.32 1.29 COUGH / COLD 5.19 5.06 CARDIO 1.04 0.93 GASTRO 1.76 1.69 The ORG ranks of some our top brands have improved and are as follows: Brands JUN MA
Slide 4: Key molecules and International Generics
Alembic’s key molecules continued to excel in the current quarter. ‘Azithral’ grew faster than the molecule (Azithromycin) growth. Azithral has recorded Rs. 105 crores of sales on MAT basis. It is the first Alembic brand to reach Rs. 100 Crores mark in ORG IMS. Alembic has five brands in the list of
Slide 5: International & API Business
¾ International & API Business Export API recorded sales of Rs. 64.96 crores against Rs. 104.07 crores. De-growth is on account lower orders from important customer. Company expect to recover some of this sales in remaining quarters. Domestic API sales during the quarter is Rs. 37.17 crores against
Slide 6: Interest and Scheme of Rearrangement
Interest Net Interest costs during the quarter were lower at Rs. 4.41 crores compared to Rs. 8.08 crores largely on account of reduction in borrowing levels. Scheme of Rearrangement: The Board of Directors of the Company in its meeting held on 29th June, 2010 has approved scheme of arrangement conta
Slide 7: Financial and Operating Result - Q1FY11
(Rs in Lacs) Financial and Operating Result - Q1FY11 Particulars Q1FY11 Q1FY10 Gr % Income from Operations 27982 29108 -4% Total Expenditure 25148 26057 -3% - (Increase) / decrease in stock (595) 956 - Consumption of Raw Material 10728 6162 - Consumption of Traded Goods 4546 8377 -5% - Employee cost
Slide 8: Sales and Profit break up
Business Performance - Rs. Sales Lacs Particulars Formulations Bulk Total Q1FY11 Q1FY10 Gr % Q1FY11 Q1FY10 Gr % Q1FY11 Q1FY10 Gr % Domestic 14496 13744 5% 3717 2108 76% 18213 15852 15% Export - Regulatory 2697 1873 44% 4013 9076 -56% 6710 10949 -39% Export - ROW 661 925 -29% 2483 1331 87% 3144 2256